Insider Transactions in Q4 2025 at Cytek Biosciences, Inc. (CTKB)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2025
|
Valerie Barnett CHIEF LEGAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,817
-1.74%
|
$39,085
$5.53 P/Share
|
|
Nov 18
2025
|
Valerie Barnett CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
24,307
+5.06%
|
-
|
|
Nov 18
2025
|
Philippe Busque SVP, GLOBAL SALES AND SERVICES |
SELL
Payment of exercise price or tax liability
|
Direct |
1,885
-2.26%
|
$9,425
$5.53 P/Share
|
|
Nov 18
2025
|
Philippe Busque SVP, GLOBAL SALES AND SERVICES |
BUY
Exercise of conversion of derivative security
|
Direct |
7,371
+8.09%
|
-
|
|
Nov 18
2025
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,123
-0.02%
|
$25,615
$5.53 P/Share
|
|
Nov 18
2025
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
21,031
+0.09%
|
-
|
|
Nov 18
2025
|
William D. Mc Combe Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,228
-3.85%
|
$31,140
$5.53 P/Share
|
|
Nov 18
2025
|
William D. Mc Combe Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,371
+10.6%
|
-
|
|
Nov 18
2025
|
Wenbin Jiang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
27,406
-0.13%
|
$137,030
$5.53 P/Share
|
|
Nov 18
2025
|
Wenbin Jiang PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
69,641
+0.32%
|
-
|
|
Nov 18
2025
|
Richard Chin |
BUY
Exercise of conversion of derivative security
|
Direct |
6,107
+37.5%
|
-
|
|
Nov 18
2025
|
Michael Holder |
BUY
Exercise of conversion of derivative security
|
Direct |
2,181
+15.0%
|
-
|